IBKS No2 SPAC
GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disea… Read more
IBKS No2 SPAC (204840) - Total Assets
Latest total assets as of September 2025: ₩46.46 Billion KRW
Based on the latest financial reports, IBKS No2 SPAC (204840) holds total assets worth ₩46.46 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
IBKS No2 SPAC - Total Assets Trend (2015–2024)
This chart illustrates how IBKS No2 SPAC’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
IBKS No2 SPAC - Asset Composition Analysis
Current Asset Composition (December 2024)
IBKS No2 SPAC's total assets of ₩46.46 Billion consist of 44.8% current assets and 55.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩4.26 Billion | 10.0% |
| Accounts Receivable | ₩5.81 Billion | 13.7% |
| Inventory | ₩8.55 Billion | 20.2% |
| Property, Plant & Equipment | ₩18.13 Billion | 42.7% |
| Intangible Assets | ₩1.68 Billion | 4.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how IBKS No2 SPAC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: IBKS No2 SPAC's current assets represent 44.8% of total assets in 2024, a decrease from 73.8% in 2015.
- Cash Position: Cash and equivalents constituted 10.0% of total assets in 2024, up from 8.5% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is property, plant & equipment at 42.7% of total assets.
IBKS No2 SPAC Competitors by Total Assets
Key competitors of IBKS No2 SPAC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Elixxer Ltd
PINK:ELIXF
|
USA | $2.17 Million |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
|
Yuyu Pharma Inc
KO:000225
|
Korea | ₩202.42 Billion |
IBKS No2 SPAC - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - IBKS No2 SPAC generates 0.61x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - IBKS No2 SPAC is currently not profitable relative to its asset base.
IBKS No2 SPAC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.26 | 1.53 | 2.08 |
| Quick Ratio | 0.58 | 0.85 | 1.73 |
| Cash Ratio | 0.00 | 0.58 | 0.00 |
| Working Capital | ₩4.19 Billion | ₩ 6.08 Billion | ₩ 8.31 Billion |
IBKS No2 SPAC - Advanced Valuation Insights
This section examines the relationship between IBKS No2 SPAC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.01 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 6.5% |
| Total Assets | ₩42.44 Billion |
| Market Capitalization | $41.34 Million USD |
Valuation Analysis
Below Book Valuation: The market values IBKS No2 SPAC's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: IBKS No2 SPAC's assets grew by 6.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for IBKS No2 SPAC (2015–2024)
The table below shows the annual total assets of IBKS No2 SPAC from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩42.44 Billion | +6.45% |
| 2023-12-31 | ₩39.87 Billion | -2.41% |
| 2022-12-31 | ₩40.85 Billion | +28.09% |
| 2021-12-31 | ₩31.89 Billion | -8.73% |
| 2020-12-31 | ₩34.94 Billion | +31.63% |
| 2019-12-31 | ₩26.55 Billion | -15.89% |
| 2018-12-31 | ₩31.56 Billion | +110.11% |
| 2017-12-31 | ₩15.02 Billion | +21.62% |
| 2016-12-31 | ₩12.35 Billion | +39.33% |
| 2015-12-31 | ₩8.86 Billion | -- |